OCUL Phase 3 readout: a negative outcome, -21.3%

On April 29, 2026, OTX-TKI (axitinib implant) — Ocular Therapeutix, Inc. (Neovascular Age-Related Macular Degeneration) reached its Phase 3 readout. The result was a negative outcome, and the stock moved -21.3% in the window around the event. It had already run -21.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.